Oxycodone News and Research RSS Feed - Oxycodone News and Research

Minister Ambrose calls for proposals to tackle prescription drug abuse

Minister Ambrose calls for proposals to tackle prescription drug abuse

The Honourable Rona Ambrose, Minister of Health, today issued a national Call for Proposals to improve the prescribing practices for prescription drugs that have a high risk of abuse or addiction. [More]
FDA approves Targiniq ER to treat severe pain

FDA approves Targiniq ER to treat severe pain

Today, the U.S. Food and Drug Administration approved Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets), an extended-release/long-acting (ER/LA) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. [More]
Physician describes ways to combat post-cancer pain

Physician describes ways to combat post-cancer pain

More and more people are surviving their cancer. Unfortunately, sometimes survival can come with pain. Although many people won't feel any pain after their cancer treatment, some may have chronic, bothersome pain. [More]
BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA). [More]

FDA issues Complete Response Letter to QRxPharma regarding Moxduo NDA

QRxPharma Limited announced today the United States Food and Drug Administration has issued a Complete Response Letter regarding the Moxduo New Drug Application for the treatment of moderate to severe acute pain. [More]
Braeburn announces new clinical trial for Probuphine based on clear guidance from FDA

Braeburn announces new clinical trial for Probuphine based on clear guidance from FDA

Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015. [More]

Regulators vote against approving new painkiller

A key government panel Tuesday voted unanimously against approval of a powerful opioid prescription painkiller intended to provide faster relief with fewer side effects. At the conclusion of a hearing, the Food and Drug Administration advisory committee voted 14-0 against recommending that the agency approve Moxduo, the first drug to combine morphine and oxycodone into one capsule (Stein, 4/22). [More]
First Edition: April 23, 2014

First Edition: April 23, 2014

Today's headlines include a range of health policy news reports, including developments related to the health law, to the marketplace and at the state level. [More]
First Edition: April 16, 2014

First Edition: April 16, 2014

Today's headlines include a report detailing how changes in the Census Bureau's annual survey could mask the health law's impact. [More]
TSRI scientists to study effects of pain medication on prenatal brain development

TSRI scientists to study effects of pain medication on prenatal brain development

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded a $472,500 Cutting Edge Basic Research Award (CEBRA) by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health to study models of the brain development of newborns who have been exposed-and become addicted-to prescription pain medication while still in the womb. [More]
Egalet provides business update, reports full year 2013 financial results

Egalet provides business update, reports full year 2013 financial results

Egalet Corporation ("Egalet") today reported business highlights and financial results for the year ended December 31, 2013. This marks the first time that Egalet is reporting its operating results as a public company. [More]
Research roundup: New medical coding system; choosing a hospice; revamping Medicare

Research roundup: New medical coding system; choosing a hospice; revamping Medicare

On October 1, 2014, all health plans, health data clearinghouses, and health care providers that transmit health information electronically must use a new, significantly broader, coding system, called ICD-10, for diagnoses and inpatient procedures. [More]
Prescriptions of opioid analgesics increased during U.S. emergency department visits

Prescriptions of opioid analgesics increased during U.S. emergency department visits

George Washington University (GW) researchers report dramatic increases in prescriptions of opioid analgesics, such as Percocet, Vicodin, oxycodone and Dilaudid, during U.S. emergency department visits from 2001 to 2010. [More]
Costs for medications expected to rise by 3 – 5% in all health care settings in 2014

Costs for medications expected to rise by 3 – 5% in all health care settings in 2014

Costs for medications are expected to rise by three to five percent in all health care settings in 2014, according to a report published online ahead of print, by the American Journal of Health-System Pharmacy (AJHP), the professional journal of the American Society of Health-System Pharmacists (ASHP). [More]
Research roundup: Palliative care and ACOs; employers and Supreme Court case on contraception

Research roundup: Palliative care and ACOs; employers and Supreme Court case on contraception

In preparation for the new ACO environment, leaders recognized the contribution palliative care can make to health care "value," especially in the care of our sickest (and most expensive) patients ... [More]
Study reveals that more than 14% of pregnant women are prescribed opioids for pain

Study reveals that more than 14% of pregnant women are prescribed opioids for pain

More than 14 percent of pregnant women were prescribed opioids (narcotics) for pain at some time during their pregnancy, according to a study posted to the online version of Anesthesiology. [More]
Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Pfizer announces results from Phase 3 study of ALO-02 in patients with chronic low back pain

Pfizer Inc. (NYSE: PFE) announced today top-line results from a Phase 3 study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain. [More]
Chemists able to trace narcotics substances, prescription drugs in Swedish wastewater

Chemists able to trace narcotics substances, prescription drugs in Swedish wastewater

Chemists at Ume- University in Sweden have been able to trace narcotics substances and prescription drugs in measurements of wastewater from 33 Swedish sewage treatment plants. Cocaine, amphetamine, and methamphetamine, in measurable concentrations, were found in a total of half of the locations. [More]
Scientists investigate factors that influence choice of abused drugs

Scientists investigate factors that influence choice of abused drugs

Prescription opioid abuse has reached epidemic levels in the past 15 years. Scientists investigating why people favor one drug over another have found that oxycodone and hydrocodone are the drugs of choice for 75% of opioid-dependent individuals. [More]
FDA accepts Purdue Pharma's Targiniq ER Tablets CII NDA for review

FDA accepts Purdue Pharma's Targiniq ER Tablets CII NDA for review

Purdue Pharma L.P. today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application for Targiniq ER (oxycodone HCl/naloxone HCl controlled-release) Tablets CII, for the management of chronic pain. [More]